Prosecution Insights
Last updated: April 19, 2026
Application No. 18/037,556

METHOD FOR CARRYING OUT REACTION OF ISATIN COMPOUND AND CYCLOPROPENONE COMPOUND AT LOW CATALYTIC AMOUNT

Non-Final OA §101§112
Filed
Nov 26, 2023
Examiner
FETTEROLF, BRANDON J
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Soochow University
OA Round
1 (Non-Final)
48%
Grant Probability
Moderate
1-2
OA Rounds
4y 1m
To Grant
60%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allow Rate
84 granted / 177 resolved
-12.5% vs TC avg
Moderate +13% lift
Without
With
+13.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
80 currently pending
Career history
257
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
28.5%
-11.5% vs TC avg
§102
19.6%
-20.4% vs TC avg
§112
28.4%
-11.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 177 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status The preliminary amendment filed on 11/26/2023 is acknowledged. Claims 1-10 are currently pending and under consideration Information Disclosure Statement The information disclosure statement filed on 6/08/2023 is acknowledged and has been considered except where lined through. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 8-10 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because claim 8 recites “An application an amine compound and a silicon amino rare earth compound in the reaction of an isatin and a cyclopropenone compound”. In the instant case, it would appear that Applicants are attempting to potentially claim a method of use of an amine compound and silicon rare earth compound in a reaction of an isatin and a cyclopropenone compound Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8-10 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. As noted above, it appears that Applicants are attempting to claim a method or process. However, the claims fail to recite any method steps for this method or process. Claim 8 recites the limitation "the reaction". There is insufficient antecedent basis for this limitation in the claim. The examiner suggests amended to be “a reaction” Allowable Subject Matter Claims 1-7 appear to be free of the prior art and in condition for allowance. The closest prior art to the instant invention is considered to be CN106432052A1 to Soochow University (2017-02-22, IDS) whom teaches a method of preparing spiro[cyclopropane-1,3’-indole] compounds by, under anhydrous and oxygen-free conditions, reacting a substituted isatin, phosphite and olefin under a silicon amino rare earth metal as catalyst in an organic solvent. The prior art does not specifically teach or suggest using a cyclopropenone as the olefin. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRANDON J FETTEROLF whose telephone number is (571)272-2919. The examiner can normally be reached M-F 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. BRANDON J. FETTEROLF, PHD Primary Patent Examiner Art Unit 1626 /BRANDON J FETTEROLF/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Nov 26, 2023
Application Filed
Jan 23, 2026
Non-Final Rejection — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594274
METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD
2y 5m to grant Granted Apr 07, 2026
Patent 12595245
INHIBITORS OF MET KINASE
2y 5m to grant Granted Apr 07, 2026
Patent 12577233
SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME
2y 5m to grant Granted Mar 17, 2026
Patent 12570640
2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
2y 5m to grant Granted Mar 10, 2026
Patent 12570615
NEW QUINAZOLINONE DERIVATIVES
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
48%
Grant Probability
60%
With Interview (+13.0%)
4y 1m
Median Time to Grant
Low
PTA Risk
Based on 177 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month